Chemomab Therapeutics (CMMB)

• Market cap: $11M
• 1 day: 1.32%
• 5 days: -11.56%
• 1 month: -5.56%
• 3 months: -23.5%
• 6 months: -20.31%
• Year to date: -14.53%
• 1 year: -68.65%
• 5 years: -98.15%
• 10 years: -99.78%
• Sector: Healthcare
• Industry: Biotechnology

About: Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Employees: 12